People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Space / Aerospace, Other Technology, Other Energy, Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Space Exploration Technologies Corp | — | Space / Aerospace | Growth/Late | $9.0B | $4.4B | 2009 |
| Tesla, Inc. | — | Other Technology | Series D+ | $246.6M | $632.7M | 2009 |
| Mythic Inc. | — | Other Technology | Series B | $102.8M | $250.0M | 2016 |
| Synthetic Genomics Inc | — | Other Energy | Series B | $55.0M | $116.0M | 2013 |
| Vannevar Technology, Inc. | — | Other Technology | Series B | $46.7M | $883.2M | 2015 |
| Better Meat Co. | — | Other | Series B | $37.0M | $146.8M | 2025 |
| GlycosBio Inc. | — | Biotechnology | Series A | $12.3M | $6.9M | 2009 |
| Zainar Inc. | — | Other Technology | Series A | $11.7M | $202.6M | 2021 |
| Xtime Inc | — | Other Technology | Seed | $3.5M | $119.7M | 2011 |
| Jildy, Inc. | — | Other Technology | Pre-Seed | $650K | $27.5M | 2011 |
Steve Jurvetson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steve Jurvetson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Antonio Gracias | 2 | 15 |
| Elon Musk | 2 | 6 |
| Kimbal Musk | 2 | 5 |
| Steve R Jurvetson | 2 | 3 |
| David Smith | 1 | 42 |
| Andrew Perlman | 1 | 15 |
| Matt Ocko | 1 | 13 |
| Ira Ehrenpreis | 1 | 10 |
| Barry Schuler | 1 | 9 |
| Andreas Stavropoulos | 1 | 8 |
| Christopher Thompson | 1 | 8 |
| Dan Watkins | 1 | 8 |
| Antonio J. Gracias | 1 | 7 |
| Steve Westly | 1 | 7 |
| Juan Enriquez | 1 | 6 |
| David Harris | 1 | 6 |
| Paul Campbell | 1 | 6 |
| Andrew Preston | 1 | 5 |
| Gregory T. Lucier | 1 | 4 |
| Shahin Farshchi | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.